Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis
Michele Bottosso(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Fabio Girardi(London School of Hygiene & Tropical Medicine), Christian Zurlo(Istituto Oncologico Veneto), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Federica Miglietta(University of Padua), Anna Chiara Cattelan(Istituto Oncologico Veneto), Daniela Iannaccone(University of Padua)
Cited by 6
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290